(DMAC) DiaMedica Therapeutics Inc. Business Model Canvas Research

DiaMedica Therapeutics Inc. depends on institutional review boards and regulators to clear trial design, safety monitoring, and informed consent before any patient enrollment or major protocol change. For drug studies, this oversight is not optional: the U.S. FDA still requires IND clearance, and IRB approval must stay current for each site and amendment.

• Review protocol design and risk
• Approve informed consent language
• Clear enrollment before start
• Vet major trial amendments

Academic nephrology and stroke centers give DiaMedica Therapeutics Inc. direct access to chronic kidney disease and acute ischemic stroke patients, plus strong key opinion leader support. These sites also raise scientific credibility, which matters because chronic kidney disease affects about 1 in 10 adults worldwide and stroke remains a leading cause of death and disability.

• Targeted patient access
• Stronger KOL backing
• Higher trial credibility
• Supports future adoption

DM300 is DiaMedica Therapeutics Inc.'s second pipeline asset, expanding the company beyond DM199 with a preclinical program for inflammatory conditions. Current work centers on assay development, pharmacology, and toxicology planning, which are the key steps before first-in-human studies.

• 2-asset pipeline: DM199 and DM300
• Preclinical focus: inflammation
• Core work: assays, pharmacology, tox

DiaMedica Therapeutics Inc. must turn Phase 2/3 trial outputs into regulatory-grade evidence, with rigorous statistical analysis, safety review, and clean document prep for future filings. For a biotech, this is the gate from raw patient data to decisions that can move a program forward or stop it fast.

• Statistical analysis of trial endpoints
• Safety review and adverse-event checks
• Submission-ready reports and filings

DiaMedica Therapeutics Inc.'s REDUX and REMEDY2 trial datasets are core regulatory-grade assets: they guide dose selection, safety review, and which program gets priority next. In biotech, that evidence base is often worth more than a single asset, because it lowers clinical risk and sharpens the next study design.

• REDUX and REMEDY2 data support dose decisions
• Safety signals shape go/no-go calls
• Regulatory evidence de-risks funding and execution

DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota, and its small internal team runs research, clinical development, and corporate functions in-house. For a clinical-stage Company Name, experienced staff are a core asset because they keep trial design, regulator work, and funding decisions tightly aligned.

• Minneapolis-based headquarters
• Internal team handles core functions
• Experience matters in clinical-stage execution

DiaMedica Therapeutics Inc. is advancing one lead molecule across renal and neurological disease, so the same R&D asset can address two large markets with one program. That platform fit can lift pipeline efficiency: one manufacturing base, one safety package, and lower capital drag versus building separate assets.

• One molecule, two indications
• Renal and neurological upside
• Shared work lowers pipeline cost
• More optionality, less asset risk

DM300 extends DiaMedica Therapeutics Inc. beyond DM199 by opening a second, preclinical path into inflammation, so the company’s pipeline is not tied to one lead asset. That matters because it broadens research scope now, while keeping long-term value creation alive if DM300 advances past the preclinical stage.

• Preclinical inflammatory expansion
• Broader pipeline than DM199 alone
• Supports longer-term value creation

Scientific and KOL engagement is central for DiaMedica Therapeutics Inc. in nephrology and stroke, where opinion leaders help shape clinical acceptance and trial design; stroke affects about 795,000 people in the U.S. each year, so early expert buy-in matters. Frequent scientific exchange can refine endpoints, while KOL support also prepares the market for future adoption.

• Drives clinical credibility.
• Sharpens development strategy.
• Builds future market education.

DiaMedica Therapeutics Inc. keeps investors informed through quarterly earnings materials, trial-readout updates, and SEC filings such as Form 10-K and Form 10-Q. Clear disclosure matters for a public biotech company because capital access depends on trust, and the company had $38.8 million in cash and cash equivalents as of its last reported quarter.

• Quarterly earnings and trial updates
• SEC reporting: 10-K, 10-Q, 8-K
• Transparent disclosure supports capital access

Scientific conferences and poster sessions are a key disclosure channel for DiaMedica Therapeutics Inc., letting it share early clinical and preclinical data with stroke and nephrology specialists, where 2025 annual meetings can reach thousands of attendees and shape trial awareness fast. For a company still in clinical development, this low-cost channel helps build credibility before late-stage readouts.

• Shares early data with specialists
• Supports stroke and nephrology visibility
• Builds trial credibility at meetings

Peer-reviewed publications help DiaMedica Therapeutics Inc. validate the science behind DM199 and DM300, and they put the data in front of clinicians, researchers, and potential partners. Strong journal output can lift credibility and support partnering, especially when the company is still building external awareness.

• Builds scientific credibility
• Reaches key medical audiences
• Supports partnering interest

Stroke neurologists and hospital systems are the gatekeepers for REMEDY2 adoption: they drive diagnosis, treatment choice, and protocol use across acute care. In the United States, stroke affects nearly 795,000 people a year, so winning these accounts matters for later-stage commercialization and repeat use.

• Key prescribers and pathway owners
• Hospital formulary and protocol access
• Critical for scale after approval

DiaMedica Therapeutics Inc. is still clinical-stage, so future licensing and pharma partners are a core customer segment. These buyers can fund development, take regional rights, or handle commercialization, which can create non-dilutive value before any product sale.

• Clinical-stage partner demand
• Development funding and rights deals
• Commercial launch support
• Non-dilutive value creation

R&D salaries and benefits are a fixed cost base for DiaMedica Therapeutics Inc., because the company needs scientists, clinical experts, regulatory staff, and operations support to run 2 active development programs. This payroll spend is tied to execution, not sales, so it stays high even before any product revenue.

• Fixed cost base for core talent
• Biology, regulatory, and ops skills
• Supports 2 active programs

DiaMedica Therapeutics Inc. carries fixed public-company costs for audit, legal, SEC reporting, and investor relations, which add recurring overhead even before product revenue. For a listed biotech, these expenses are unavoidable and usually sit inside SG&A, pressuring cash burn and shortening runway.

• Audit and legal fees are recurring
• SEC reporting adds ongoing cost
• Investor relations raises overhead
• Public listing makes these fixed

If DiaMedica Therapeutics Inc. out-licenses a partnered asset and it reaches market, the company could earn royalties on net sales. That matters because royalties can scale with partner sales, while DiaMedica avoids most manufacturing and distribution costs; in biotech, royalty rates often land in the single digits to low teens, so 5% on $100 million of sales would equal $5 million.

• Partner sales can create long-term upside
• Low direct manufacturing exposure
• Typical late-stage biotech monetization

Research collaboration payments can come from sponsored studies or cost-sharing deals, giving DiaMedica Therapeutics Inc. non-dilutive cash that helps cover R&D spend. In FY2025, this stream would matter most as a way to widen external funding beyond equity and keep more capital for core pipeline work.

• Sponsored research cash
• Shared development costs
• Reduces R&D burden
• Broadens funding sources